pharmaphorum2y
Verona builds case for COPD drug ensifentrine as filing nears
Verona Pharma is looking odds on for a regulatory approval for its chronic obstructive pulmonary disease (COPD) therapy ensifentrine, after chalking up a second positive phase 3 trial. The Anglo ...
pharmaphorum2d
Verona cuts $400m loan deal as it preps COPD drug for market
Verona Pharma has agreed a new $400 million debt facility with Oxford Finance and Hercules Capital designed to help the company navigate the possible approval and launch of ensifentrine ...
Business Insider3d
Verona Pharma Reports Strong Ohtuvayreâ„¢ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...
Business Insider10d
Verona Delivers 250% Return In Less Than A Year
Ensifentrine, marketed under the brand name Ohtuvayre, is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre, which secured FDA ...
CNN5y
Verona Pharma plc Sponsored ADR
It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February ...
Stockhouse9d
Verona Pharma Reports Strong Ohtuvayre(TM) Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease ...